Plain-English translation of NCT07295509 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called (also known as IBI112) as a treatment for psoriatic arthritis—a condition that causes joint pain, swelling, and skin rashes. The study will give some people the new medication through injections, while others receive a placebo (inactive treatment) for the first 26 weeks, then switch to the real medication. Researchers want to see if this treatment can reduce joint symptoms and improve quality of life.
Many people with psoriatic arthritis don't respond well enough to current treatments like NSAIDs or older medications. This study exists to find out whether this new medication could be a better option for patients who need more effective relief.
You likely qualify if…
You likely don't qualify if…
You would receive subcutaneous injections (shots under the skin) at scheduled visits over about 6 months or longer. Half of participants receive the new medication on one of two dosing schedules, while the other half receive placebo injections for the first 26 weeks, then switch to the active medication. Researchers will check your joint symptoms, skin, physical function, and overall quality of life at multiple visits to see how well the treatment works.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China